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A B S T R A C T
Purpose
Dexamethasone is a key component in the treatment of pediatric acute lymphoblastic leukemia
(ALL), but can induce serious adverse effects. Recent studies have led to the hypothesis that
neuropsychological adverse effects may be a result of cortisol depletion of the cerebral miner-
alocorticoid receptors. We examined whether including a physiologic dose of hydrocortisone in
dexamethasone treatment can reduce neuropsychologic and metabolic adverse effects in chil-
dren with ALL.
Patients and Methods
We performed a multicenter, double-blind, randomized controlled trial with a crossover design. Of
116 potentially eligible patients (age 3 to 16 years), 50 were enrolled and were treated with two
consecutive courses of dexamethasone in accordance with Dutch Childhood Oncology Group ALL
protocols. Patients were randomly assigned to receive either hydrocortisone or placebo in a circadian
rhythm (10 mg/m2/d) during both dexamethasone courses. Primary outcome measure was parent-
reported Strength and Difﬁculties Questionnaire in Dutch, which assesses psychosocial problems.
Other end points included questionnaires, neuropsychological tests, and metabolic parameters.
Results
Of 48 patients who completed both courses, hydrocortisone had no signiﬁcant effect on outcome;
however, a more detailed analysis revealed that in 16 patients who developed clinically relevant
psychosocial adverse effects, addition of hydrocortisone substantially reduced their Strength and
Difﬁculties Questionnaire in Dutch scores in the following domains: total difﬁculties, emotional
symptoms, conduct problems, and impact of difﬁculties. Moreover, in nine patients who de-
veloped clinically relevant, sleep-related difﬁculties, addition of hydrocortisone reduced total
sleeping problems and disorders of initiating and maintaining sleep. In contrast, hydrocortisone
had no effect on metabolic parameters.
Conclusion
Our results suggest that adding a physiologic dose of hydrocortisone to dexamethasone treatment
can reduce the occurrence of serious neuropsychological adverse effects and sleep-related difﬁ-
culties in pediatric patients with ALL.
J Clin Oncol 34:2287-2293. © 2016 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Dexamethasone has high antileukemic activity and
excellent penetration into the CNS; thus, dexa-
methasone is commonly included in the treatment
of pediatric acute lymphoblastic leukemia (ALL).1-4
Unfortunately, however, dexamethasone treatment
can cause robust neuropsychological and metabolic
adverse effects. The reported frequency of patients
who develop dexamethasone-related adverse effects
that encompass mood, behavior, cognition, and
sleep ranges from 5% to 75%.5-10 Of importance,
patients and their families report that these adverse
effects are most detrimental with respect to quality
of life.5-10 Because many current ALL treatment
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protocols call for pediatric patients with ALL to receive pulses of
dexamethasone for approximately 1.5 years, these adverse effects can
have a major impact on the daily activities and development of the
child.5,9,11 To date, only one intervention study has been performed
to investigate glucocorticoid-induced neuropsychological adverse
effects. This study found that chlorpromazine and lorazepam re-
duced glucocorticoid-related symptoms12; however, because these
agents can induce other adverse effects, including drowsiness,
orthostatic hypotension, and paradoxical agitation, they should
therefore only be prescribed for severe behavioral problems
and/or psychosis.
Until recently, the pathophysiology of dexamethasone-related
neuropsychological adverse effects was poorly understood.7 For
example, excessive activation of cerebral glucocorticoid receptors
(GRs) by corticosteroid binding has been suggested to underlie
neuropsychological adverse effects7; however, recent data have
revealed that mineralocorticoid receptors (MRs) in the brain may
play an even more important role in the regulation of mood,
behavior, cognition, and sleep.13,14 In the human brain, GRs and
MRs have similar expression patterns; however, these two receptor
types have strikingly different ligand afﬁnities.15 For example,
dexamethasone has a 30- to 40-fold higher afﬁnity for the GR than
cortisol, whereas dexamethasone does not bind to the MR. In
contrast, prednisolone binds the GR, but has a low afﬁnity for the
MR.16 Finally, cortisol, that is, hydrocortisone, can bind both
receptor types but has a higher afﬁnity for the MR.17 Both dexa-
methasone and prednisolone suppress production of cortisol via
a negative feedback loop that acts on the hypothalamus-pituitary-
adrenal axis16; however, prednisolone, but not dexamethasone,
can bind and activate the MR. Thus, patients who are treated
with dexamethasone have fewer cortisol-bound MRs, which
may lead to more adverse effects.18 Data from animal studies
and small case series suggest that the resulting dexamethasone-
induced cortisol depletion of MRs in the brain causes or ex-
acerbates the adverse effects with respect to mood, behavior,
and/or cognition.13,14,19,20
These key ﬁndings have led us to hypothesize that dexamethasone-
induced cortisol depletion of the MR may underlie the neuro-
psychological adverse effects in pediatric patients with ALL.21
Therefore, we examined whether these adverse effects can be re-
duced by adding physiologic dosages of hydrocortisone to dexa-
methasone treatment.21 Of importance, we previously reported that
hydrocortisone does not reduce dexamethasone sensitivity of the
cells of patients with ALL ex vivo21; therefore, we performed
a randomized controlled trial to determine whether including
hydrocortisone in dexamethasone treatment regimen reduces the
neuropsychological, metabolic, and physical adverse effects in
children with ALL.
PATIENTS AND METHODS
Study Design and Participants
We performed a randomized, placebo-controlled, double-blind trial
with a crossover design (Fig 1). The primary objective of our study was the
reduction of psychosocial problems during dexamethasone treatment. The
secondary objective was to study the inﬂuence of the addition of hy-
drocortisone during dexamethasone treatment on sleep-related difﬁculties,
eating behavior, physical activity, cognitive functions, and metabolic pa-
rameters. Patients were recruited at ﬁve Dutch pediatric oncology de-
partments. Patients with ALL (age 3 to 16 years) who were treated according
to Dutch Childhood Oncology Group ALL-10 or ALL-11 medium-risk
protocols, including dexamethasone pulses during the maintenance phase
(after asparaginase and anthracyclines were discontinued), were eligible
for inclusion. The following exclusion criteria were applied: a signiﬁcant
language barrier, evidence of preexisting intellectual disability, and any
condition that could have interfered with the administration and/or
absorption of the study medication and/or dexamethasone. Parents and
legal guardians of patients provided written informed consent, and
patients age 12 to 16 years also provided their own written informed
consent.
The part of the maintenance phase during which intervention was
conducted consisted of 19 consecutive treatment cycles that lasted 21 days
each, in which patients received ﬁve consecutive days of dexamethasone
treatment, vincristine once (ﬁrst day of the cycle), 6-mercaptopurine once
per day, and methotrexate once per week. The study included two 5-day
courses of dexamethasone (6 mg/m2/d, three doses containing 2 mg/m2
each) withwhich each patient also received either placebo or hydrocortisone—in
this crossover study, patients who were randomly assigned to receive
hydrocortisone in the ﬁrst course received placebo in the second course
and vice versa (Fig 1). The median start of the study was in the fourth cycle
after stopping asparaginase, and the median time between the two 5-day
study courses was 3.0 weeks (interquartile range [IQR], 3.0 to 6.0) or one
cycle. Daily dose of hydrocortisone was administered orally in three doses
that contained 5, 3, and 2 mg/m2 at the same time as dexamethasone and
was designed to follow the normal circadian rhythm. Placebo was ad-
ministered in a dose and scheme similar to those of hydrocortisone. A
wash-out period of $ 16 days was included between dexamethasone
treatment courses.
Random assignment
n = 50
Dexamethasone +
hydrocortisone
Dexamethasone +
hydrocortisone
Dexamethasone +
placebo
Study Course 2
Testing Days
1 2 3 4 5 1 2 3 4 5
1
Group 1
n = 23
Group 2
n = 23
Group 1
n = 25
Group 2
n = 25
Treatment Days
Study Course 1
Dexamethasone +
placebo
2 3 4
Fig 1. Study design.
2288 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Warris et al
Downloaded from ascopubs.org by Erasmus MC - Medische Bibliotheek on February 27, 2018 from 145.005.120.040
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Procedures
The primary end point was the total difﬁculties score from the
parent-reported Strengths and Difﬁculties Questionnaire in Dutch (SDQ-
Dut; Data Supplement). Secondary end points were obtained from ad-
ditional questionnaires, neuropsychological tests (Data Supplement), and
metabolic parameters. In each course, mood, behavior, cognition, and
sleep were assessed on the morning of the ﬁrst day of treatment, that is,
before the start of dexamethasone treatment, and the morning of the ﬁfth
treatment day, that is, after a full 4 days of dexamethasone treatment.
Questionnaires. Parent-reported SDQ-Dut, which assesses psycho-
social difﬁculties and strengths, has been validated in the Dutch pop-
ulation. The SDQ-Dut22-25 is a brief questionnaire that assesses the
psychosocial functioning of children and adolescents age 3 to 16 years by
either parent reporting or self-reporting (for patients age 11 to 16 years).
The questionnaire contains 25 items in the following ﬁve subscales (score
ranges are in the Data Supplement): emotional symptoms, conduct prob-
lems, hyperactivity and inattention, peer relationship problems, and pro-
social behavior. We calculated the total difﬁculties score, which is deﬁned as
the sum of the ﬁrst four subscale scores, that is, excluding prosocial behavior.
The impact of these difﬁculties on the life of the child wasmeasured by using
the impact of stress score. A higher SDQ total difﬁculties score reﬂects more
problems. Ideally, both parents and all patients age$ 11 years completed the
SDQ-Dut on all four testing days. On each testing day, participants were
instructed to provide information regarding psychosocial problems ex-
perienced in the previous four days. SDQ-Dut scores obtained from the
primary parent, deﬁned as the parent who was present in the outpatient
clinic at all four testing days, were used for all analyses. In the majority of
cases, the primary parent was the mother of the patient.
The Sleep Disturbance Scale for Children (SDSC)26 was used to
assess sleep quality and sleep disturbances in patients. The SDSC has
a combined score that covers the six most common sleep disorders
experienced during childhood, which are disorders of initiating and
maintaining sleep (DIMS), sleep breathing disorders, disorders of arousal,
sleep-wake transition disorders (SWTDs), disorders of excessive somno-
lence (DES), and sleep hyperhidrosis. A higher score reﬂects the presence
of more problems.
The Dutch Eating Behavior Questionnaire for children (DEBQ-C)27
has three subscales: restrained eating, emotional eating, and external
eating. A higher score on each subscale reﬂects the presence of more
problems.
Daily physical activity was measured by using the Baecke Physical
Activity Questionnaire (BPAQ),28 which consists of 16 questions organized
in three sections—school activity, sports activity, and leisure activity. With
the BPAQ, a higher score on each scale reﬂects higher activity.
Neuropsychological assessment. Neuropsychological tests that were
designed for children and young adults were used to assess skills in four
domains: memory, attention, visual-spatial functions, and processing speed
(Data Supplement). The neuropsychological tests were performed by the
same investigator (L.T.W.) on all four testing days.
Physical parameters, anthropometric measurements, and laboratory
tests. Parents and children were instructed to maintain a diary of the dietary
activity of the child during the ﬁrst four treatment days in each study course
(Data Supplement). Height (meters), weight (kilograms), waist-hip cir-
cumference (centimeters), and blood pressure (millimeters of mercury)
were measured on all four testing days.
Physical activity was measured throughout both courses by using
a Philips DirectLife activity monitor.29 Fasting blood samples (whole
blood) were taken between 8 AM and 10 AM and were used to analyze lipid
proﬁles (triglycerides, cholesterol, HDL, and LDL) and glucose and
insulin levels.
Adverse Events
Adverse events, deﬁned as any adverse change in condition between
the ﬁrst dose and 16 days after the last dose, were assessed in accordance
with the US National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.0.30
Statistical Analysis
Data were analyzed for carry-over effects and for period, that is, order
of treatment, effects by using paired Student’s t test—each patient served as
his or her own control.31 In each treatment course, a delta score, that is, the
difference between two scores, was calculated by subtracting the score on
treatment day 1 from the score on treatment day 5. The treatment effect
was assessed by comparing the delta-placebo score with the delta-
hydrocortisone score by using paired Student’s t test with normally dis-
tributed values or the Wilcoxon signed-rank test. Adjusted P values
(Benjamin-Hochberg procedure) are reported in the Data Supplement. A
nested subset analysis was used to evaluate the effect of hydrocortisone in
children who experienced clinically relevant dexamethasone-related ad-
verse effects. Clinically relevant psychosocial adverse effects were deﬁned as
a change of $ 5 in parent-reported SDQ total difﬁculties score during the
respective placebo course. This difference represents approximately one
standard deviation in the general population.22 Clinically relevant sleeping
problems were deﬁned as a change of $ 7 (one standard deviation) in the
total SDSC score during the respective placebo course.26,32 In the subset
analysis, we examined the effect size rather than the P value because of the
potential inﬂuence of regression to the mean in the subgroup selection.
RESULTS
Enrollment
During the recruitment period, 50 (49.5%) of 116 potentially
eligible patients enrolled at the ﬁve pediatric oncology departments
from July 2012 through February 2015. The most frequently cited
reasons for not participating in the study were the high burden
of two extra visits (37 patients) and an absence of a priori
dexamethasone-related adverse effects (eight patients; Fig 2). After
patients were randomly assigned to treatment groups, two patients
left the trial after the ﬁrst course as a result of dexamethasone-
related osteonecrosis and were excluded from the efﬁcacy analyses.
Treatment groups were similar with respect to age, type of leu-
kemia, treatment protocol, and CNS status at diagnosis (Data Sup-
plement). Two patients did not complete the parent-reported SDQs
at all four time points and were therefore excluded from the efﬁcacy
analysis. Four patients developed serious adverse events after the ﬁrst
study course (two hydrocortisone courses and two placebo courses),
with three of these patients developing febrile neutropenia (grade 2 to
3), and one patient developing osteomyelitis (grade 3). These serious
adverse events were not considered related to study medication, and
all four patients remained in the study. Adverse events were similar
between the hydrocortisone and placebo courses, which indicated
that no hydrocortisone-speciﬁc adverse events were observed
(Data Supplement). No carry-over effect (P = .34; independent
samples Student’s t test) or period effect (P = .76; Mann-Whitney
test) was observed on the basis of the primary outcome.
Psychosocial Problems
SDQ results obtained from 46 primary parents (41 mothers
and 5 fathers) were analyzed to evaluate the psychosocial problems
of the children. Four days of dexamethasone treatment signiﬁ-
cantly increased patient problems as reported by all SDQ scales and
subscales. In 30 (65%) of 46 patients, dexamethasone induced an
increase in psychosocial problems, deﬁned as a $ 1-point change
in the SDQ total difﬁculties score, during the placebo course. One
third of the population did not have any increase in SDQ total
difﬁculties with dexamethasone. Median SDQ total difﬁculties
www.jco.org © 2016 by American Society of Clinical Oncology 2289
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score of the entire study group on treatment day 5 in the placebo
course was 9.5, which was within the normal range.
In the entire group, addition of hydrocortisone did not affect
the total difﬁculties score (mean difference, 20.8 6 5.5; P = .33),
emotional symptoms (mean difference, 20.6 6 2.3; P = .08),
conduct problems (mean difference, 0.06 1.5; P = 1.00), or other
SDQ subscales compared with the placebo course (Fig 3).
However, when we examined the effect of hydrocortisone on the
subset of 16 patients who had clinically relevant dexamethasone-
related adverse effects, that is, an increase of $ 5 in their SDQ total
difﬁculties score, we found that hydrocortisone had a clinically sig-
niﬁcant treatment effect. In these 16 children, hydrocortisone had
a clear effect on the total difﬁculties delta-score compared with
placebo (median difference,25.0; IQR,27.8 to23.0; Fig 3). In ﬁve
(31%) of 16 patients, total difﬁculties score decreased from a high
score in the placebo course to a score in the normal range with the
addition of hydrocortisone. We also observed a signiﬁcant effect of
hydrocortisone versus placebo on emotional symptoms (median
difference,21.5; IQR,24.0 to21.0), conduct problems (median
difference, 21.0; IQR, 22.0 to 0.0), and impact of stress scores
(median difference, 21.0; IQR, 22.0 to 0.0; Fig 3). Real SDQ
scores and for point estimates (95% CI) of median differences are
reported in the Data Supplement.
With respect to their baseline characteristics, the patient group
with clinically relevant dexamethasone-induced adverse effects did
not differ signiﬁcantly from the group of patients without clinically
relevant dexamethasone-induced psychosocial adverse effects. The
week of maintenance phase in which the patients participated did
not inﬂuence adverse effects (P = .47). Child-reported SDQ scores
(n = 10) did not differ signiﬁcantly from their respective parent-
reported scores (P = .44).
Sleep
Parents of 47 children completed the SDSC questionnaire on all
four testing days. Dexamethasone treatment alone, that is, the pla-
cebo course, signiﬁcantly increased the disorders of arousal (P = .04),
SWTD (P = .01) and DES (P = .01) scores. In the entire pa-
tient group, hydrocortisone had no signiﬁcant effect on SDSC
scores (SDSC total score: P = .84; DIMS: P = .74; DES: P = .29;
SWTD: P = .29; Fig 4); however, when the nine children (19%)
who had clinically relevant dexamethasone-induced sleeping prob-
lems, deﬁned as a change of $ 7 in SDSC total score during the
placebo course, were analyzed separately, hydrocortisone reduced
both the SDSC total scores (median difference, 211.0; IQR, 216.0
to 0.0) and DIMS scores (median difference, 23.0; IQR, 27.0 to
–0.5; Fig 4). The majority of patients with clinically relevant sleeping
problems also experienced clinically relevant psychosocial adverse
effects during dexamethasone treatment (n = 7; 78%).
Neuropsychological Functioning
Neuropsychological tests revealed that dexamethasone treat-
ment alone had no effect on attention (auditory attention, response
set, and inhibition), visual-spatial functions (design copying),
memory (narrativememory andmemory for designs), or processing
speed; however, addition of hydrocortisone signiﬁcantly improved
Screened patients
(N = 116)
Eligible patients
(n = 101)
Patients enrolled
(n = 50)
Randomly assigned (n = 25)
 Course 1: Hydrocortisone
 Course 2: Placebo
Group 1
  
  
  
  
Refusals (n = 51)
Burden too high (n =  38)
No side effects of dexamethasone(n = 8)
No participation in studies (n = 3)
Refused to drink oral solutions (n = 2)
   
     
    
   
    
      
Excluded (n = 15)
Discontinuation of dexamethasone (n = 4)
Hydrocortisone stress dose (n = 4)
Too many toxicities (n = 2)
Left for treatment abroad (n = 2)
Language barrier (n = 2)
Died after screening (n = 1)
Incomplete for SDQ 
analysis (n = 2)
Assessed for primary
end point (n = 23)
Discontinued after course 1
(stop of dexamethasone; n = 2)
Assessed for primary
end point (n = 23)
Completed two study
courses (n = 25)
Group 2
Randomly assigned (n = 25)
 Course 1: Placebo
 Course 2: Hydrocortisone
Completed two study
courses (n = 23)
Fig 2. CONSORT diagram. SDQ, Strengths and
Difﬁculties Questionnaire.
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long-term visual memory (P = .01; n = 47; Data Supplement).
Hydrocortisone had no effect on other neuropsychological tests of
attention, visual-spatial function (NEPSY [A Developmental
Neuropsychological Assessment]), or processing speed (Wechsler;
Data Supplement). The neuropsychological performance of the
children with clinically relevant dexamethasone-induced psycho-
social adverse effects was similar to the neuropsychological per-
formance of the entire group.
Metabolism
Physical activity data measured by using BPAQ, were available
for 36 patients, and activity monitor data were available for 41
patients. Physical activity was neither affected by dexamethasone
nor by hydrocortisone addition.
Dietary intake and data regarding eating behavior measured
by using DEBQ-C were available for 44 and 17 patients, respec-
tively (Data Supplement). Hydrocortisone had no signiﬁcant effect
on energy intake (P = .88). Similarly, the addition of hydrocor-
tisone had no signiﬁcant effect on weight, height, waist-hip ratio,
blood pressure, or any laboratory values (Data Supplement).
DISCUSSION
Here, we report the results of the ﬁrst randomized controlled
clinical trial, to our knowledge, to investigate whether a potentially
safe intervention, that is, physiologic doses of hydrocortisone, can
be used to reduce dexamethasone-induced neuropsychological
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adverse effects in pediatric patients with ALL. Both patients and
their parents consider neuropsychological adverse effects to be the
most detrimental consequences of ALL treatment with respect to the
reduction in quality of life.2 Our results show that although hy-
drocortisone had no signiﬁcant beneﬁcial effect in the entire patient
group, hydrocortisone signiﬁcantly decreased dexamethasone-
related behavioral difﬁculties, emotional disorders, and sleep prob-
lems speciﬁcally in patients who experienced the most severe
neuropsychological adverse effects. This ﬁnding is particularly rel-
evant as psychosocial problems can be present in up to two thirds
of children with ALL, and one half of the problems can be cate-
gorized as clinically relevant. Thus, our results indicate that these
emotional and behavioral problems can be reduced in these
children, thereby markedly improving quality of life.33 More-
over, sleeping problems—one half of which were categorized as
clinically relevant—have been reported in 43% of patients, and
reducing these problems may also improve quality of life.34
Conversely, these ﬁndings suggest that adding hydrocortisone
does not beneﬁt all children with ALL. One third of the population
did not have any neuropsychological adverse effects with dexa-
methasone treatment. This patient variability in adverse effects
may be explained by genetics,35 glucocorticoid sensitivity,36 or
dexamethasone clearance (higher drug levels).37 Occurrence of neu-
ropsychological adverse effects was independent of age, in contrast to
Mrakotsky et al,38 who reported more neurobehavioral problems in
younger children. It should be mentioned that subgroups are small,
and regression to the mean could have inﬂuenced our subgroup
selection and that our results should be conﬁrmed, preferably, in
a validation study in selected patients with symptoms only;
however, the substantial effect size of the intervention indicates
a beneﬁt of hydrocortisone in patients with psychosocial prob-
lems and sleeping problems.
Hydrocortisone addition did improve one speciﬁc memory
score. As a result of the absence of acute dexamethasone-induced
impairment of cognitive function, clinical relevance of this ﬁnding
is limited. Absence of dexamethasone-induced short-term cog-
nitive impairment is in accordance with the study of Wingenfeld
et al36 who did not ﬁnd an effect of high-dose dexamethasone on
working memory in healthy volunteers.
Of interest, hydrocortisone also had no effect on the metabolic
adverse effects of dexamethasone. This lack of efﬁcacy may be
caused by a different pathophysiology of metabolic adverse
effects. This notion is supported by the absence of a signiﬁcant
difference in body weight change during induction therapy—an
important metabolic adverse effect of high dose glucocorti-
coids, for example, prednisolone—between children with neuro-
psychological adverse effects and childrenwithout neuropsychological
adverse effects. It is conceivable that metabolic adverse effects are
not caused by cortisol depletion of the cerebral MRs.
In conclusion, our current study suggests that including
a physiologic dose of hydrocortisone decreases clinically rele-
vant dexamethasone-induced psychosocial problems and sleep-
ing problems in pediatric patients with ALL. For a validation
study, it is important to identify patients who will beneﬁt from
hydrocortisone treatment by using SDQ-Dut and SDSC. Phys-
iologic doses of hydrocortisone are relatively inexpensive, provide
a naturally occurring hormone, and have no apparent negative
effects. This novel, yet simple, intervention has the potential
to signiﬁcantly reduce neuropsychological adverse effects in
patients who receive high-dose dexamethasone treatment.
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